Physician profile
Mark A Landrio
NPI 1063441533
$631,413.60
in general payments reported to CMS, 2019-2025
79 companies · $116K in 2025
The $116K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113K · 2020: $66K · 2021: $72K · 2022: $81K · 2023: $65K · 2024: $118K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $212K · Travel and Lodging: $43K · Food and Beverage: $26K · Consulting Fee: $19K · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $212,256.50 |
| Travel and Lodging | $42,747.20 |
| Food and Beverage | $25,560.53 |
| Consulting Fee | $19,175.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $190,844.11 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Emd Serono, INC. | $125,141.99 | 2019-2025 | Mavenclad, Mavenclad |
| Ucb, INC. | $92,643.36 | 2019-2025 | Rystiggo, Zilbrysq, Briviact |
| Alexion Pharmaceuticals, INC. | $70,454.41 | 2019-2025 | Ultomiris, Soliris |
| Genzyme Corporation | $43,377.90 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $21,513.30 | 2020-2021 | |
| Allergan, INC. | $20,872.01 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $20,339.08 | 2022 | |
| Argenx US, INC. | $11,369.29 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Amgen INC. | $7,278.38 | 2019-2025 | Uplizna |
| Abbvie INC. | $4,483.82 | 2019-2025 | |
| Tg Therapeutics, INC. | $3,330.30 | 2023-2025 | |
| Lilly USA, LLC | $1,531.67 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Teva Pharmaceuticals USA, INC. | $1,530.56 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,113.91 | 2019-2025 |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,022.01 | 2019-2025 | |
| Eisai INC. | $939.44 | 2019-2025 | |
| Celgene Corporation | $861.63 | 2021-2025 | Zeposia |
| Genentech USA, INC. | $820.78 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Sunovion Pharmaceuticals INC. | $742.56 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $685.25 | 2019-2025 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $677.87 | 2019-2022 | |
| Grifols USA, LLC | $643.22 | 2019-2025 | Gamunex-C |
| Lundbeck LLC | $642.82 | 2019-2025 | Vyepti |
| Harmony Biosciences LLC | $623.63 | 2020-2025 | Wakix |
| Horizon Therapeutics Plc | $610.77 | 2021-2023 | Uplizna, Tepezza |
| Amneal Pharmaceuticals LLC | $576.70 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Acorda Therapeutics, INC | $491.55 | 2019-2023 | Inbrija |
| Tanabe Pharma America, INC. | $391.41 | 2019-2025 | Radicava |
| Sk Life Science, INC. | $335.70 | 2020-2024 | Xcopri |
| Mallinckrodt Hospital Products INC. | $334.13 | 2021-2025 | Acthar |
| Acadia Pharmaceuticals INC | $332.95 | 2019-2022 | |
| Genentech, INC. | $329.11 | 2022-2023 | Ocrevus |
| Sumitomo Pharma America, INC. | $327.47 | 2023-2024 | Aptiom |
| Greenwich Biosciences, INC. | $288.55 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $281.63 | 2019-2025 | |
| Axsome Therapeutics, INC. | $266.97 | 2023-2025 | Sunosi, Symbravo |
| Avanir Pharmaceuticals, INC. | $232.30 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $182.18 | 2019-2022 | |
| Csl Behring | $182.17 | 2019-2025 | Hizentra |
| Inspire Medical Systems, INC. | $173.88 | 2021-2023 | Inspire |
| Vanda Pharmaceuticals INC. | $164.55 | 2025 | Ponvory |
| Adamas Pharmaceuticals, INC. | $158.43 | 2019-2021 | |
| Mdd US Operations, LLC | $156.90 | 2019-2023 | Gocovri |
| Abbott Laboratories | $148.67 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $147.41 | 2021-2022 | |
| Dynasplint Systems INC. | $139.79 | 2019 | |
| Arbor Pharmaceuticals, INC. | $134.54 | 2019-2021 | |
| Kyowa Kirin, INC. | $132.01 | 2019-2023 | Nourianz |
| E.R. Squibb & Sons, L.L.C. | $113.10 | 2021 | |
| Janssen Scientific Affairs, LLC | $110.30 | 2024 | |
| Fisher & Paykel Healthcare INC | $108.82 | 2020-2024 | Fisher & Paykel Healthcare |
| Neurelis, INC. | $105.26 | 2020-2024 | Valtoco |
| Ge Healthcare | $99.26 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $84.30 | 2023 | Purified Cortrophin Gel |
| Corium, LLC | $69.62 | 2023 | Adlarity |
| Merz Pharmaceuticals, LLC | $67.04 | 2023-2024 | Xeomin |
| Mallinckrodt Enterprises LLC | $57.34 | 2019 | |
| Insightec,INC | $54.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.73 | 2025 | Hyqvia |
| Idorsia Pharmaceuticals US INC | $44.47 | 2023 | Quviviq |
| Livanova USA, INC. | $43.73 | 2019-2020 | |
| Kedrion Biopharma, INC. | $43.34 | 2024 | Koate, Albuked, Kedrab |
| Medtronic USA, INC. | $41.92 | 2019-2020 | |
| Itamar Medical INC | $37.57 | 2024-2025 | Watchpatone |
| Aquestive Therapeutics, INC. | $30.04 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.05 | 2025 | Onpattro |
| Ns Pharma, INC. | $24.69 | 2022 | |
| Banner Life Sciences, LLC | $23.72 | 2022 | |
| Cycle Pharmaceuticals INC | $23.67 | 2025 | Bafiertam, Tascenso Odt |
| Ultragenyx Pharmaceutical INC. | $23.19 | 2024 | Dojolvi |
| Sanofi-Aventis U.S. LLC | $20.90 | 2019 | |
| Impel Pharmaceuticals INC. | $20.08 | 2023 | Trudhesa |
| Avadel Cns Pharmaceuticals, LLC | $19.08 | 2024 | Lumryz |
| Advanced Respiratory, INC | $18.00 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $17.88 | 2025 | Wainua |
| Otsuka America Pharmaceutical, INC. | $16.67 | 2024 | Nuedexta |
| Zoll Respicardia, INC. | $16.66 | 2024 | Remede System |
| Travere Therapeutics, INC. | $4.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Landrio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.